Association of anti-Mullerian hormone and small-dense low-density lipoprotein cholesterol with hepatosteatosis in young lean women with and without polycystic ovary syndrome

View/ Open
Access
info:eu-repo/semantics/openAccessDate
2014Author
Öztaş, EfserÇağlar, Gamze Sinem
Kaya, Cemil
Karadağ, Demet
Demirtaş, Selda
Kurt, Mevlüt
Pabuçcu, Recai
Metadata
Show full item recordCitation
Oztas, E., Caglar, G. S., Kaya, C., Karadag, D., Demirtas, S., Kurt, M., & Pabuccu, R. (2014). “Association of anti-Mullerian hormone and small-dense low-density lipoprotein cholesterol with hepatosteatosis in young lean women with and without polycystic ovary syndrome”. European Journal of Obstetrics & Gynecology and Reproductive Biology, 182, 240-246. https://doi.org/10.1016/j.ejogrb.2014.11.024Abstract
Objective: To study the association of anti-Mullerian hormone (AMH) and small-dense low-density
lipoprotein cholesterol (sd-LDL) with hepatosteatosis among young, lean, polycystic ovary patients.
Study design: A prospective, case control study was carried out including 79 young lean women. Fiftyeight women with polycystic ovary syndrome (PCOS) and 21 age-and BMI-matched healthy controls were recruited. Anthropometric variables, biochemical and hormonal parameters, insulin-resistance indices, lipid profiles including sd-LDL levels and serum AMH levels were determined. Hepatic lipid
content was evaluated by abdominal ultrasonography (USG). Determining the best predictor(s) which
discriminate normal USG and hepatosteatosis was analyzed by multiple logistic regression analyses.
Adjusted odds ratios and 95% confidence intervals were also calculated.
Results: PCOS patients had an increased prevalence of hepatosteatosis by 41.4% (P = 0.006) and they had
significantly higher levels of sd-LDL and AMH when compared with the control group (P < 0.001). AMH
and sd-LDL levels were positively and significantly associated with hepatosteatosis in young lean
women with and without PCOS (OR: 2.877, 95%CI: 1.453–5.699, P: 0.02 and OR: 1.336, 95%CI: 1.083–
1.648, P: 0.007, respectively). AMH and sd-LDL levels were positively correlated in PCOS patients
(r = 0.626, P < 0.001). Both sd-LDL and AMH levels were the most predictive parameters for the
determination of hepatosteatosis within the PCOS group. (OR: 3.347, 95%CI: 1.348–8.313, P = 0.009 and OR: 1.375, 95%CI: 1.072–1.764, P = 0.012, respectively). Statistically significant higher levels of AMH were associated with hepatosteatosis both in insulin resistance (IR) positive and IR negative PCOS
patients (P < 0.001).
Conclusion: Hepatosteatosis is common in young lean PCOS patients. Increased AMH and sd-LDL levels may independently predict hepatosteatosis in young lean women with and without PCOS